A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window

Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure

“…6 Besides, it has been previously proven that patients receiving personalized antiplatelet therapy based on CYP2C19 genotype were more likely to achieve a better response. 24 We observed differences among cardiovascular risk factors, previous ischemic and hemorrhagic events, and type of intervention between sexes; however, we consider these differences not clinically relevant. In addition, in analyzing the influence of these factors in patient outcome, we observed that the type of intervention affects the treatment duration, being higher in both flow diverter and stent applications, compared to coils.…”

“…In this respect, CYP2C19 genotyping and quantifying the aggregation value can help to determine whether a patient could be at risk . Besides, it has been previously proven that patients receiving personalized antiplatelet therapy based on CYP2C19 genotype were more likely to achieve a better response …”

Genotype‐guided antiplatelet treatment versus conventional therapy: A systematic review and meta‐analysis

“…A total of 10 561 patients from 16 studies (eight RCTs and eight cohort studies) were included in the meta-analysis, 7,[28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] of which 5798 (54.90%) underwent genotype-guided therapy and the others underwent conventional therapy. A flow diagram of the identification and selection of study is presented in Figure 1.…”

Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery

“…The CAPITAL Registry is a revascularization registry that includes baseline characteristics, pharmacotherapies, procedural details, and clinical outcomes of all patients undergoing coronary angiography at the University of Ottawa Heart Institute (UOHI). [10][11] The UOHI Perioperative Cardiac Anesthesia and Surgical Database is a complementary registry which provides pre-, intra-, and postoperative clinical variables of all patients referred for coronary artery bypass grafting. The UOHI has approval from its institutional research ethics board to analyze and publish de-identified data collected prospectively during the perioperative period.…”